J. Sobell

发表

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

B. Strober, A. Gottlieb, A. Kavanaugh, 2012, Dermatology and Therapy.

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

A. Kimball, C. Zouboulis, G. Jemec, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Overview of biologic agents in medicine and dermatology.

J. Sobell, 2005, Seminars in cutaneous medicine and surgery.

Systemic therapies for psoriasis: understanding current and newly emerging therapies.

J. Sobell, S. J. Hallas, 2003, Seminars in cutaneous medicine and surgery.

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

B. Strober, A. Gottlieb, A. Kavanaugh, 2012, Dermatology and Therapy.

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

B. Strober, A. Gottlieb, A. Kavanaugh, 2012, Dermatology and Therapy.

Defining drug‐free remission of skin disease in patients with plaque psoriasis

A. Menter, K. Gordon, A. Armstrong, 2019, The British journal of dermatology.

The role of TNF inhibitors in psoriatic disease.

B. Mandell, J. Sobell, 2014, Seminars in cutaneous medicine and surgery.

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021

N. Konnikov, D. Rosmarin, J. Sobell, 2022, JAAD international.

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

C. Leonardi, C. Ryan, B. Hendrickson, 2018, American Journal of Clinical Dermatology.

Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis

A. Menter, K. Papp, I. Caro, 2008, Drug safety.

Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.

G. Girolomoni, P. Foley, U. Mrowietz, 2016, Acta dermato-venereologica.

Update on IL-17 Inhibitors for Psoriasis

A. Levin, J. Sobell, 2017, Current Dermatology Reports.

Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice

A. Fleischer, K. Papp, J. Crowley, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.

Elizabeth J Horn, B. Strober, A. Gottlieb, 2009, Journal of the American Academy of Dermatology.

Successful treatment of a widespread inflammatory verrucous epidermal nevus with etanercept.

J. Dover, J. Sobell, M. Bogle, 2006, Archives of dermatology.

Vesicles in a patient with a lichenoid eruption--quiz case.

M. Stadecker, J. Sobell, J. Lee, 2003, Archives of dermatology.

Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial

B. Strober, K. Duffin, M. Okun, 2012, The British journal of dermatology.

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.

M. Lebwohl, L. Puig, H. Bachelez, 2020, Journal of the American Academy of Dermatology.

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open‐label study

C. Leonardi, U. Mrowietz, M. Okun, 2012, The British journal of dermatology.

Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.

G. Mulder, C. Ryan, E. Giamarellos‐Bourboulis, 2017, Wounds (King of Prussia, Pa.).

Patient-reported outcomes among patients with hidradenitis suppurativa experiencing different levels of clinical response: Integrated analysis from two clinical studies

G. Mulder, Rakesh K. Singh, T. Tzellos, 2018, Journal of the American Academy of Dermatology.

Successful treatment of hand and foot psoriasis with efalizumab therapy.

Loretta Jones, J. Crowley, J. Sobell, 2006, Journal of drugs in dermatology : JDD.

Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial.

A. Kimball, H. A. Xia, E. Boh, 2007, Journal of drugs in dermatology : JDD.

Patient fatalities potentially associated with efalizumab use.

Jeffrey M Weinberg, J. Weinberg, Jeffrey M Sobell, 2009, Journal of drugs in dermatology : JDD.

Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents.

J. Weinberg, J. Sobell, R. Kalb, 2009, Journal of drugs in dermatology : JDD.

Healthcare Resource Utilization and Baseline Characteristics of Patients With Generalized Pustular Psoriasis: Real-World Results From a Large US Database of Multiple Commercial Medical Insurers

S. Feldman, C. Leonardi, R. Bohn, 2021 .